var data={"title":"Metyrapone: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metyrapone: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6574?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">see &quot;Metyrapone: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12806507\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Metopirone</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060385\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent, Hypothalamic-Pituitary ACTH Function</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060379\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">see &quot;Metyrapone: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>ACTH function, diagnostic test:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single-dose/overnight test: <b>Note:</b> Due to potential precipitation of acute adrenal insufficiency (crisis) in some patients, experts suggest that metyrapone should be used with extreme caution in an outpatient setting; consider administration in an inpatient environment (Kliegman 2016; U&ccedil;ar 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: Oral: 30 mg/kg as a single dose given at midnight the night before the test; maximum dose: 3,000 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple-dose test: Children and Adolescents: Oral: 15 mg/kg/dose every 4 hours for 6 doses; <b>minimum</b> dose: 250 mg/dose; maximum dose: 750 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>ACTH function testing</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Single-dose/overnight test: Oral: 30 mg/kg (maximum: 3 <b>g</b>) at midnight</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Multiple-dose test: Oral: 750 mg every 4 hours for 6 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195988\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metopirone: 250 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195977\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345045\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Metopirone&reg; is available from HRA Pharma via special allocation only. Contact the manufacturer for additional information at 855-674-7663.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060389\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single-dose/overnight test:<b> Note:</b> Due to potential precipitation of acute adrenal insufficiency (crisis) in some patients, experts suggest that metyrapone should be used with extreme caution in an outpatient setting; consider administration in an inpatient environment (Kliegman 2016; U&ccedil;ar 2016). Administer dose at midnight with yogurt or milk. Blood samples should be collected the following morning (7:30 to 8:00 am). Administer prophylactic dose of cortisone acetate after samples are obtained.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple-dose test: Administer with milk or snack 3 days following ACTH test. Urine is collected for 24 hours following administration of last dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195995\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Do not store above 30&deg;C (86&deg;F); protect from heat. Protect from moisture.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060388\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Diagnostic agent for testing hypothalamic-pituitary ACTH function (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196020\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MetyraPONE may be confused with metyroSINE</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196019\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, sedation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Allergic skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal discomfort, abdominal pain, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatetning: Bone marrow depression, decreased white blood cell count</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195991\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to metyrapone or any component of the formulation; patient with adrenal cortical insufficiency</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195980\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Reduced adrenal secretory capacity: Acute adrenal insufficiency may be induced in patients with reduced adrenal secretory capacity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Thyroid disease: Response to test may be subnormal in patients with hypo- or hyperthyroidism. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50811714\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administration of metyrapone may induce acute adrenal insufficiency in patients with reduced adrenal secretory capacity; should be used with extreme caution in an outpatient setting; consider administration in an inpatient environment. Patients should be observed closely during administration and the following day; should only be administered under the supervision of a qualified physician experienced in the use of metyrapone (Kliegman 2016; U&ccedil;ar 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196012\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2A6 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195983\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12607&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acetaminophen: MetyraPONE may increase the serum concentration of Acetaminophen. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism towards the oxidative route that produces a hepatotoxic metabolite. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of MetyraPONE. The oral metyrapone test would thus be unreliable unless the metapyrone dosage was substantially increased (e.g., 750 mg every 2 hours).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: MetyraPONE may increase serum concentrations of the active metabolite(s) of Propacetamol. Specifically, metyrapone may increase acetaminophen exposure. More importantly, by inhibiting the conjugative metabolism of acetaminophen, metyrapone may shift the metabolism toward the oxidative route that produces a hepatotoxic metabolite. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195985\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195992\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adequate animal reproduction studies have not been conducted. When used as a diagnostic test during the second and third trimesters of pregnancy, the fetal pituitary responded to the enzymatic block. A subnormal response to testing may occur in pregnant women.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Untreated Cushing syndrome during pregnancy may cause adverse events in the mother and fetus (Bronstein 2015; Kamoun 2014). Use of metyrapone for the treatment of Cushing syndrome has been noted in case reports (Bronstein 2015; Nieman 2015). When medical therapy is needed, treatment is generally started in the second or third trimesters (Bronstein 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14787784\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Single-dose test: ACTH, cortisol and 11-deoxycortisol concentrations measured at 8 am (U&ccedil;ar 2016); 11-deoxycortisol concentrations diagnostic for adrenal insufficiency:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: &lt;210 nmol/L (U&ccedil;ar 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: &lt;200 nmol/L (Wallace 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Multiple-dose test: Normal response following the test is a two- to fourfold urinary increase in 17-OHCS excretion or doubling of 17-KGS excretion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060387\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Normal 24-hour urinary excretion of 17-OHCS: 3 to 12 mg (increases following ACTH infusion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Normal response to metyrapone:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Plasma ACTH: 44 pmol/L (200 ng/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Plasma 11-desoxycortisol: Pediatric: 0.21 micromoles/L (U&ccedil;ar 2016); Adult: 0.2 micromoles/L (70 mcg/L)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">24 hour urinary excretion of 17-OHCS: 2 to 4 time increase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">24 hour urinary excretion of 17-KGS: 2 time increase</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">A subnormal response may be indicative of panhypopituitarism or partial hypopituitarism. An excessive response is suggestive of Cushing syndrome associated with adrenal hyperplasia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345064\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Metyrapone inhibits the production of cortisol; blockade can be measured by the urinary increase of the metabolites of cortisol precursors in the urine (17-hyroxycorticosteroids [17-OHCS] and 17-ketogenic steroids [17-KGS]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11345066\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Peak steroid excretion: Within 24 hours of administration</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Oral: Well absorbed; rapid </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Reduced to metyrapol (active metabolite); parent drug and metabolite also undergo glucuronide conjugation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Metyrapone: 1.9 &plusmn; 0.7 hours; Metyrapol (active metabolite): Takes twice as long as metyrapone to be eliminated </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine; ~5% as metyrapone (primarily as glucuronide conjugate) and ~38% as metyrapol (primarily as glucuronide conjugate)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323397\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Metopirone Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg (18): $381.47</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038679\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Metopiron (CH, GB, NL, NO, SE);</li>\n      <li>Metopirone (AU, CZ, FR, GR, HK, IE, IL, MT, NZ, PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bronstein MD, Machado MC, Fragoso MC. Management of endocrine disease: Management of pregnant patients with Cushing's syndrome. <i>Eur J Endocrinol</i>. 2015;173(2):R85-R91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/25872515/pubmed\" target=\"_blank\" id=\"25872515\">25872515</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hotham NJ, Ilett KF, Hackett LP, et al. Transfer of metyrapone and its metabolite, rac-metyrapol, into breast milk. <i>J Hum Lact. </i>2009; 25(4):451-454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/19759353/pubmed\" target=\"_blank\" id=\"19759353\">19759353</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kamoun M, Mnif MF, Charfi N, Kacem FH, Naceur BB, Mnif F, Dammak M, et al. Adrenal diseases during pregnancy: pathophysiology, diagnosis and management strategies. <i>Am J Med Sci</i>. 2014;347(1):64-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/23514671/pubmed\" target=\"_blank\" id=\"23514671\">23514671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metopirone (metyrapone) [prescribing information]. Farmingdale, NJ: Direct Success, Inc.; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nieman LK, Biller BM, Findling JW, et al; Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2015;100(8):2807-2831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/26222757/pubmed\" target=\"_blank\" id=\"26222757\">26222757</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U&ccedil;ar A, Ba&#351; F, Saka N. Diagnosis and management of pediatric adrenal insufficiency. <i>World J Pediatr</i>. 2016;12(3):261-274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/27059746/pubmed\" target=\"_blank\" id=\"27059746\">27059746</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace I, Cunningham S, Lindsay J. The diagnosis and investigation of adrenal insufficiency in adults. <i>Ann Clin Biochem. </i>2009;46(Pt 5):351-367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metyrapone-pediatric-drug-information/abstract-text/19675057/pubmed\" target=\"_blank\" id=\"19675057\">19675057</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12607 Version 82.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F12806507\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060385\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060379\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195988\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F195977\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F11345045\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060389\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F195995\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060388\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F196020\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196019\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195991\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195980\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F50811714\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F196012\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195983\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195985\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195992\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F14787784\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1060387\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F11345064\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F11345066\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323397\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038679\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12607|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metyrapone-drug-information\" class=\"drug drug_general\">Metyrapone: Drug information</a></li></ul></div></div>","javascript":null}